Aurinia Pharmaceuticals (AUPH) Reports Q2 Loss, Tops Revenue Estimates

This article was originally published on Nasdaq

Aurinia Pharmaceuticals (AUPH) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.37 per share a year ago. These figures are adjusted for non-recurring items.